X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB CIPLA UNICHEM LAB/
CIPLA
 
P/E (TTM) x 281.7 33.8 832.8% View Chart
P/BV x 0.6 3.1 21.1% View Chart
Dividend Yield % 2.6 0.6 472.4%  

Financials

 UNICHEM LAB   CIPLA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
CIPLA
Mar-18
UNICHEM LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs382663 57.6%   
Low Rs234479 48.9%   
Sales per share (Unadj.) Rs116.3189.0 61.5%  
Earnings per share (Unadj.) Rs-18.917.6 -107.5%  
Cash flow per share (Unadj.) Rs-11.734.0 -34.5%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %1.60.5 308.9%  
Book value per share (Unadj.) Rs381.0176.7 215.6%  
Shares outstanding (eoy) m70.34805.12 8.7%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x2.63.0 87.7%   
Avg P/E ratio x-16.332.5 -50.2%  
P/CF ratio (eoy) x-26.216.8 -156.3%  
Price / Book Value ratio x0.83.2 25.0%  
Dividend payout %-26.417.1 -155.0%   
Avg Mkt Cap Rs m21,668459,724 4.7%   
No. of employees `0002.323.6 9.7%   
Total wages/salary Rs m2,00626,901 7.5%   
Avg. sales/employee Rs Th3,587.86,446.1 55.7%   
Avg. wages/employee Rs Th880.01,139.4 77.2%   
Avg. net profit/employee Rs Th-583.7600.0 -97.3%   
INCOME DATA
Net Sales Rs m8,180152,193 5.4%  
Other income Rs m6103,577 17.1%   
Total revenues Rs m8,790155,769 5.6%   
Gross profit Rs m-1,32028,264 -4.7%  
Depreciation Rs m50513,228 3.8%   
Interest Rs m801,142 7.0%   
Profit before tax Rs m-1,29517,470 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-28 7.9%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m332,501 1.3%   
Profit after tax Rs m-1,33114,166 -9.4%  
Gross profit margin %-16.118.6 -86.9%  
Effective tax rate %-2.614.3 -18.0%   
Net profit margin %-16.39.3 -174.8%  
BALANCE SHEET DATA
Current assets Rs m23,318108,141 21.6%   
Current liabilities Rs m4,63538,322 12.1%   
Net working cap to sales %228.445.9 497.9%  
Current ratio x5.02.8 178.3%  
Inventory Days Days12297 125.5%  
Debtors Days Days12174 163.2%  
Net fixed assets Rs m8,163109,411 7.5%   
Share capital Rs m1411,610 8.7%   
"Free" reserves Rs m26,660140,682 19.0%   
Net worth Rs m26,801142,292 18.8%   
Long term debt Rs m336,621 0.0%   
Total assets Rs m31,890228,606 13.9%  
Interest coverage x-15.216.3 -93.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.30.7 38.5%   
Return on assets %-3.96.7 -58.6%  
Return on equity %-5.010.0 -49.9%  
Return on capital %-4.510.0 -45.6%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35651,691 8.4%   
Fx outflow Rs m021,033 0.0%   
Net fx Rs m4,35630,658 14.2%   
CASH FLOW
From Operations Rs m-1,12314,628 -7.7%  
From Investments Rs m16,487-8,540 -193.1%  
From Financial Activity Rs m-8,811-3,855 228.6%  
Net Cashflow Rs m6,5522,431 269.5%  

Share Holding

Indian Promoters % 50.1 16.0 313.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 15.1 12.2 123.8%  
FIIs % 3.0 23.7 12.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 31.7 26.2 121.0%  
Shareholders   20,176 161,166 12.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   DIVIS LABORATORIES  WOCKHARDT LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 22, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS